期刊文献+

黄芪多糖对维甲酸诱导骨质疏松大鼠的影响

Effect of astragalus polysaccharides on osteoporosis induced by retinoic acid in rats
原文传递
导出
摘要 [目的]探究不同浓度的黄芪多糖对维甲酸诱导的骨质疏松大鼠的影响。[方法] 50只SD大鼠随机分为对照组、模型组、低剂量组、中剂量组和高剂量组,每组10只。除对照组外其他各组予以70 mg/kg维甲酸连续灌肠18 d,对照组使用等体积蒸馏水灌肠。之后,予以黄芪多糖灌胃,低剂量组(100 mg/kg)、中剂量组(200 mg/kg)和高剂量组(400 mg/kg),对照组和模型组使用等体积蒸馏水,用药第30 d后,行大鼠左侧股骨大体、 BMD、生物力学检测,检测血清TNF-α和TGF-β1浓度,检测骨均浆蛋白。[结果]股骨重量由高至低依次为对照组>高剂量组>中剂量组>低剂量组>模型组[(1.1±0.2) g vs (1.0±0.1) g vs (0.9±0.2) g vs (0.8±0.1) g vs (0.6±0.0) g, P<0.001],对照组与高剂量组间骨重差异无统计学意义(P>0.05)。BMD依次为对照组>高剂量组>中剂量组>低剂量组>模型组[(252.5±21.2) mg/cm^(2)vs (232.7±21.4) mg/cm^(2)vs (190.6±31.2) mg/cm^(2)vs (158.1±13.1) mg/cm^(2)vs(119.9±12.2) mg/cm^(2), P<0.001],对照组与高剂量组间BMD差异无统计学意义(P>0.05)。力学测试的最大载荷排序同上,组间差异有统计学意义(P<0.05)。血清检测TNF-α排序为对照组<高剂量组<中剂量组<低剂量组<模型组,组间差异有统计学意义(P<0.05);血清检测TGF-β1排序为高剂量组>对照组>中剂量组>低剂量组>模型组,组间差异有统计学意义(P<0.05)。骨均浆检测BMP-2/β-actin和p-ERK/ERK均为对照组>高剂量组>中剂量组>低剂量组>模型组,组间差异有统计学意义(P<0.05)。[结论]黄芪多糖可改善维甲酸诱导的大鼠骨质疏松症状,其机理可能是激活MAPK/ERK信号通路下游。 [Objective]To investigate the effects of different concentrations of astragalus polysaccharide on osteoporosis induced by reti-noic acid in rats.[Methods]Fifty SD rats were randomly divided into control group,model group,low-dose group,medium-dose group andhigh-dose group,with 10 rats in each group.Except the control group,the other groups were given 70 mg/kg retinoic acid continuous intra-gastrically for 18 days,and the control group was given equal volume distilled water.After that,astragalus polysaccharide was given intragas-trically,100 mg/kg in the low dose group,200 mg/kg in medium dose group and 400 mg/kg in high dose group,whereas equal volume of dis-tilled water was given in the control group and model group.At 30 days after administration,gross measurement,BMD and biomechanicaltests were performed on the left femur of rats.Serum concentrations of TNF-αand TGF-β1 and bone homogenate protein were measured.[Results]The femur weight in descending order was control group>high dose group>medium dose group>low dose group>model group[(1.1±0.2)g vs(1.0±0.1)g vs(0.9±0.2)g vs(0.8±0.1)g vs(0.6±0.0)g,P<0.001],with no significant difference in bone weight between control groupand high-dose group(P>0.05).BMD was ranked as control group>high dose group>medium dose group>low dose group>model group[(252.5±21.2)mg/cm^(2) vs(232.7±21.4)mg/cm^(2) vs(190.6±31.2)mg/cm^(2) vs(158.1±13.1)mg/cm^(2) vs(119.9±12.2)mg/cm^(2),P<0.001],and therewas no significant difference in BMD between the control group and the high-dose group(P>0.05).The order of maximum load in mechani-cal test was the same as above,with statistically significant differences among groups(P<0.05).The order of serum TNF-αdetection was ofcontrol group<high dose group<medium dose group<low dose group<model group,with statistically significant differences among them(P<0.05).The order of serum TGF-β1 was of high dose group>control group>medium dose group>low dose group>model group,with statisticallysignificant differences(P<0.05).Bone homogenate measured BMP-2/β-actin and P-ERK/ERK were as follows:control group>high dosegroup>medium dose group>low dose group>model group,with statistical significances(P<0.05).[Conclusion]Astragalus polysaccharidecan improve the osteoporosis induced by retinoic acid in rats,and its mechanism may be the activation of the downstream MAPK/ERK signal-ing pathway.
作者 熊金华 樊志强 戴钦正 曾有文 XIONG Jin-hua;FAN Zhi-qiang;DAIQin-zheng;ZENG You-wen(Department of Orthopedics,Jinxian Hospital,Jiangxi Provincial People's Hospital,Nanchang 331700,Chi-na;Department of Orthopedics,Jiangxi Provincial People's Hospital,Nanchang 330006,China;Department of Orthopaedics,WuyuanHospital of Traditional Chinese Medicine,Shangrao 334000,China)
出处 《中国矫形外科杂志》 CAS CSCD 北大核心 2024年第19期1791-1796,共6页 Orthopedic Journal of China
基金 江西省卫生健康委科技计划项目(编号:202210157)。
关键词 黄芪多糖 大鼠骨质疏松 肿瘤坏死因子-α(TNF-α) 转化生长因子-β1(TGF-β1) MAPK/ERK信号通路 astragalus polysaccharide rat osteoporosis tumor necrosis factor-α(TNF-α) transforming growth factor-β1(TGF-β1) MAPK/ERK signal path
  • 相关文献

参考文献9

二级参考文献172

  • 1刘开心,祁永华,张喜武,胡娱,韩莹,孙晖,王喜军.基于UPLC-Q-TOF-MS技术的圣愈汤干预骨髓抑制大鼠的体内显效成分分析[J].中药药理与临床,2022,38(2):7-13. 被引量:8
  • 2Walker SE.Estrogen and autoimmune disease.Clin Rev AllergyImmunol,2011,40(1):60-65.
  • 3Djaafar S,Pierroz DD,Chicheportiche R,et al.Inhibition of Tcell-dependent and RANKL-dependent osteoclastogenic processesassociated with high levels of bone mass in interleukin-15receptor-deficient mice.Arthritis Rheum,2010,62(11):3300-3310.
  • 4Carlsten H.Immune responses and bone loss:the estrogenconnection.Immunol Rev,2005,208:194-206.
  • 5Mundy GR.Osteoporosis and inflammation.Nutr Rev,2007,65(12 Pt 2):S147-151.
  • 6Charatcharoenwitthaya N,Khosla S,Atkinson EJ,et al.Effectof blockade of TNF-alpha and interleukin-1 action on boneresorption in early postmenopausal women.J Bone Miner Res,2007,22(5):724-729.
  • 7Rachon D,Mysliwska J,Suchecka-Rachon K,et al.Effects ofoestrogen deprivation on interleukin-6 production by peripheralblood mononuclear cells of postmenopausal women.J Endocrinol,2002,172(2):387-395.
  • 8Weitzmann MN,Pacifici R.Estrogen deficiency and bone loss:an inflammatory tale.J Clin Invest,2006,116(5):1186-1194.
  • 9Lencel P,Magne D.Inflammaging:the driving force inosteoporosis?Med Hypotheses,2011,76(3):317-321.
  • 10Scheidt-Nave C,Bismar H,Leidig-Bruckner G,et al.Seruminterleukin 6 is a major predictor of bone loss in women specific tothe first decade past menopause.J Clin Endocrinol Metab.2001,86(5):2032-2042.

共引文献340

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部